Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Recruiting now · Phase 3 · Has a placebo group
Conditions studied: Focal Seizure, Epilepsy, Focal Epilepsy
In brief
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.
Key facts
- Study ID
- NCT07563881
- Run by
- Rapport Therapeutics Inc.
- People needed
- 333
- Starts
- 2026-06-05
- Expected to finish
- 2029-09-01
- Last updated by the study team
- 2026-08-05
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18 - 75
- BMI 18-45 kg/m2
- Diagnosis of focal epilepsy for ≥24 months prior to Visit 1
- Report from at least 1 brain MRI or CT scan and 1 EEG study, each completed within 10 years prior to Visit 1, consistent with focal epilepsy diagnosis
- Concomitant use of between 1 and 3, inclusive, antiseizure medication(s) ASM(s) as maintenance, not including rescue or pro re nata (PRN) ASMs
- Ability to keep accurate daily focal seizure records using an e-diary
You may not qualify if…
- Known hypersensitivity or prior exposure to RAP-219.
- Unstable or uncontrolled serious medical, neurologic (other than focal epilepsy), or psychiatric condition that is ongoing or considered likely to recur
- Anticipated need for surgery during the study period
- Medical history of any of the following:
- generalized epilepsy
- focal preserved consciousness without observable manifestations (also known as focal aware nonmotor) as the participant's only seizure type
- psychogenic nonepileptic seizure (PNES)
- status epilepticus or seizure clusters (when individual seizures cannot be counted) within 12 months prior to Visit 1 (Day -56).
- epilepsy surgery within 12 months prior to Visit 1 (Day -56).
- Participation in another clinical study of an investigational product within 12 weeks or 5 half-lives of this other investigational product
Where it is running
- Amicis Research Center — Palmdale, California, United States (enrolling)
- Panhandle Research and Medical Clinic, LLC — Gulf Breeze, Florida, United States (enrolling)
- Indiana University Health Fort Wayne Neurology — Fort Wayne, Indiana, United States (enrolling)
- Mid-Atlantic Epilepsy and Sleep Center — Bethesda, Maryland, United States (enrolling)
- Northeast Regional Epilepsy Group — Hackensack, New Jersey, United States (enrolling)
- Thomas Jefferson University — Philadelphia, Pennsylvania, United States (enrolling)
- Neurological Associates — Richmond, Virginia, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.